Trials / Active Not Recruiting
Active Not RecruitingNCT04906993
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 443 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | camrelizumab； famitinib malate | Camrelizumab intravenously ; Famitinib Orally |
| DRUG | platinum-based chemotherapy | Physician's choice chemotherapy |
Timeline
- Start date
- 2021-07-23
- Primary completion
- 2025-06-10
- Completion
- 2027-05-31
- First posted
- 2021-05-28
- Last updated
- 2025-09-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04906993. Inclusion in this directory is not an endorsement.